ATE535284T1 - Zusammensetzungen die non-typable haemophilus influenzae (nthi) und probiotische bakterien enthalten zur behandlung von nthi verursachten schleimhautinfektionen - Google Patents

Zusammensetzungen die non-typable haemophilus influenzae (nthi) und probiotische bakterien enthalten zur behandlung von nthi verursachten schleimhautinfektionen

Info

Publication number
ATE535284T1
ATE535284T1 AT01931225T AT01931225T ATE535284T1 AT E535284 T1 ATE535284 T1 AT E535284T1 AT 01931225 T AT01931225 T AT 01931225T AT 01931225 T AT01931225 T AT 01931225T AT E535284 T1 ATE535284 T1 AT E535284T1
Authority
AT
Austria
Prior art keywords
nthi
treatment
compositions containing
containing non
haemophilus influenzae
Prior art date
Application number
AT01931225T
Other languages
German (de)
English (en)
Inventor
Robert Clancy
Gerald Pang
Margaret Dunkley
Original Assignee
Hunter Immunology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunter Immunology Ltd filed Critical Hunter Immunology Ltd
Application granted granted Critical
Publication of ATE535284T1 publication Critical patent/ATE535284T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01931225T 2000-05-19 2001-05-21 Zusammensetzungen die non-typable haemophilus influenzae (nthi) und probiotische bakterien enthalten zur behandlung von nthi verursachten schleimhautinfektionen ATE535284T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ7612A AUPQ761200A0 (en) 2000-05-19 2000-05-19 Compositions and methods for treatment of mucosal infections
PCT/AU2001/000588 WO2001087332A1 (en) 2000-05-19 2001-05-21 Compositions and methods for treatment of mucosal infections

Publications (1)

Publication Number Publication Date
ATE535284T1 true ATE535284T1 (de) 2011-12-15

Family

ID=3821690

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01931225T ATE535284T1 (de) 2000-05-19 2001-05-21 Zusammensetzungen die non-typable haemophilus influenzae (nthi) und probiotische bakterien enthalten zur behandlung von nthi verursachten schleimhautinfektionen

Country Status (10)

Country Link
US (1) US8637051B2 (enExample)
EP (1) EP1305042B1 (enExample)
JP (2) JP5567756B2 (enExample)
KR (1) KR20030019389A (enExample)
CN (1) CN1437480A (enExample)
AT (1) ATE535284T1 (enExample)
AU (1) AUPQ761200A0 (enExample)
BR (1) BR0110971A (enExample)
CA (1) CA2409813C (enExample)
WO (1) WO2001087332A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
TWI350174B (en) * 2003-03-12 2011-10-11 Wyeth Corp Adjuvanted bovine vaccines
US20080044440A1 (en) * 2004-02-18 2008-02-21 Margaret Dunkley Vaccine Formulated For Administration To Mucosa Of The Lungs
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
CN101060858A (zh) * 2004-08-17 2007-10-24 亨特免疫有限公司 确定口服灭活疫苗剂量的方法
WO2006017895A1 (en) * 2004-08-17 2006-02-23 Hunter Immunology Pty Limited Oral killed vaccines and method for providing same
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
EP2547603B1 (en) 2010-03-18 2014-05-07 Eveready Battery Company, Inc. Button cell battery dispenser package
KR101768118B1 (ko) * 2010-06-25 2017-08-14 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 기도 감염의 치료를 위한 방법 및 약학 조성물
WO2013028756A1 (en) 2011-08-22 2013-02-28 Carnegie Mellon University Atom transfer radical polymerization under biologically compatible conditions
CN106456740B (zh) * 2014-05-02 2021-06-08 Qu生物制药公司 抗微生物免疫调节
US9982070B2 (en) 2015-01-12 2018-05-29 Carnegie Mellon University Aqueous ATRP in the presence of an activator regenerator
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
AU2021252164B2 (en) 2020-04-09 2026-07-02 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
CN111529703B (zh) * 2020-06-17 2023-09-15 湖南循天然营养有限公司 一种组合物及其制备方法与在制备免疫佐剂中的应用
WO2024234034A1 (en) * 2023-05-12 2024-11-21 Biomune Pty Ltd Compositions and methods for preventative treatments for mucosal associated ailments

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA907737B (en) * 1989-09-29 1991-07-31 Nisshin Oil Mills Ltd Stable immunogen composition for oral administration
US6231870B1 (en) * 1995-06-02 2001-05-15 Uab Research Foundation Oral administration of pneumoccal antigens
JPH0680575A (ja) * 1991-03-05 1994-03-22 Meiji Milk Prod Co Ltd 経口免疫賦活剤
AU724743B2 (en) 1996-05-31 2000-09-28 Genetics Institute, Llc IL-12 as an adjuvant for Bordetella Pertussis vaccines
EP0988053A1 (en) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
WO1999012416A1 (en) * 1997-09-09 1999-03-18 The Trustees Of Columbia University In The City Of New York T-independent conjugate-vaccines
US6153182A (en) 1997-12-19 2000-11-28 Uab Research Foundation Lymphotactin as an adjuvant
MXPA00006168A (es) * 1997-12-23 2005-02-24 Genesis Res & Dev Corp Ltd Composiciones derivadas de mycrobacterium vaccae y metodos para su uso.
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
GB9801870D0 (en) * 1998-01-28 1998-03-25 Raby Limited Vaccine composition
BR9907691B1 (pt) * 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
SE9800615D0 (sv) * 1998-02-27 1998-02-27 Ingvar Sjoeholm Mucosal microparticle conjugate vaccine
JP2002505302A (ja) 1998-03-05 2002-02-19 ザ メディカル カレッジ オブ オハイオ Ｉｌ−１２の鼻腔内イノキュレーションによる免疫の増強
US5985264A (en) * 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
FR2776521B1 (fr) * 1998-03-27 2000-12-15 Pf Medicament Utilisation de conjugues p40 actifs par voie nasale
WO2000000218A1 (fr) * 1998-06-26 2000-01-06 Aventis Pasteur Immunisation a ciblage mucosal
AR020102A1 (es) 1998-07-30 2002-04-10 Ucb Sa Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
US7223398B1 (en) * 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
US20020044926A1 (en) * 1999-12-10 2002-04-18 Gregor Reid Oral administration of lactobacillus for the treatment and prevention of urogenital infection
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
BR0111785A (pt) * 2000-06-19 2003-05-20 Candivax Pty Ltd Composições e métodos para tratamento de candidìase
AU2001284558B2 (en) * 2000-08-08 2007-01-04 Genesis Research And Development Corporation Limited Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them

Also Published As

Publication number Publication date
JP2003533489A (ja) 2003-11-11
KR20030019389A (ko) 2003-03-06
JP2012153706A (ja) 2012-08-16
EP1305042B1 (en) 2011-11-30
CA2409813C (en) 2013-11-12
US8637051B2 (en) 2014-01-28
EP1305042A4 (en) 2005-02-02
CN1437480A (zh) 2003-08-20
US20040057965A1 (en) 2004-03-25
CA2409813A1 (en) 2001-11-22
WO2001087332A1 (en) 2001-11-22
AUPQ761200A0 (en) 2000-06-15
EP1305042A1 (en) 2003-05-02
JP5567756B2 (ja) 2014-08-06
BR0110971A (pt) 2005-04-05

Similar Documents

Publication Publication Date Title
EP1305042A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SLEW-TONE INFECTIONS
DE60124080D1 (de) Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
ATE475423T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
ATE326236T1 (de) Hpv-e7 zur behandlung von menschlichem papillomavirus
ATE493433T1 (de) Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
BR0015698A (pt) Composições e métodos para tratamento de doenças alérgicas
ATE319710T1 (de) Antimikrobielle chinolonderivate und ihre verwendung zur behandlung bakterieller infektionen
DE69635783D1 (de) Antigen omp26 aus haemophilus influenzae
ATE439138T1 (de) Probiotika zur primären prävention atopischer erkrankungen
ATE430154T1 (de) Amino-substituierte cyclohexan derivate zur behandlung bakterieller infektionen
ATE314343T1 (de) Verbindungen zur behandlung der alzheimerischen krankheit
ATE392208T1 (de) Zusammensetzungen zur prävention und behandlung von erkältung und grippe-ähnlichen symptomen, die cheliertes zink enthalten
DE60001687D1 (de) Trovafloxacin enhaltende Suspensionen zur oralen Anwendung
ATE291927T1 (de) Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen
DE69840027D1 (de) Synthetische peptidkonstrukte zur erkennung und behandlung von parodontose hervorgerufen durch porphyromonas gingivalis
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
ATE355069T1 (de) Verfahren zur herstellung polyvalenter bakteriophagenpräparationen zur behandlung bakterieller infektionen
DE60231475D1 (de) Materialien und methoden zur behandlung von hepatitis c
DE602005020639D1 (de) Zusammensetzung aus milchsäure und lactoferrin
DE69419782D1 (de) Multimeres alpha-lactalbumin enthaltende antibakterielle zusammensetzung
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
DE60130906D1 (de) Die synergistischen wirkungen von hgf und antibakterieller behandlung
EP1261331A4 (en) METHOD AND COMPOSITIONS FOR TREATING FIBROSANT DISEASES
DE602005027228D1 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind